Dr. Andrew McClellan, MD
What this data tells you about Dr. McClellan
Dr. Andrew McClellan is an ophthalmology in Dallas, TX, with 14 years in practice. Based on federal Medicare data, Dr. McClellan performed 58,987 Medicare services across 4,723 unique beneficiaries.
Between the years covered by Open Payments, Dr. McClellan received a total of $5,564 from 16 pharmaceutical and/or device companies across 41 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in ophthalmology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. McClellan is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
Medicare Practice Summary
Medicare Utilization ↗Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Eye injection (Vabysmo/faricimab) | 45,962 | $29 | $83 |
| Retinal imaging (OCT scan) | 3,308 | $31 | $100 |
| Aflibercept eye injection (Eylea) | 2,926 | $687 | $2,244 |
| Eye injection for retinal disease | 2,144 | $96 | $1,173 |
| Comprehensive eye exam, established patient | 903 | $92 | $200 |
| Injection, pegcetacoplan, intravitreal, 1 mg | 902 | $120 | $333 |
| Office visit, established patient (30-39 min) | 499 | $84 | $170 |
| Eye exam, established patient, focused | 375 | $62 | $200 |
| Office visit, established patient (20-29 min) | 363 | $67 | $110 |
| Injection, ranibizumab, 0.1 mg | 251 | $182 | $498 |
| Injection, dexamethasone, intravitreal implant, 0.1 mg | 238 | $158 | $429 |
| Principal care management services for a single high-risk disease, first 30 minutes of clinical staff time directed by health care professional, per calendar month | 220 | $47 | $130 |
| Comprehensive eye exam, new patient | 177 | $109 | $275 |
| Unclassified drugs | 176 | $1,997 | $6,523 |
| Injection, ranibizumab-eqrn (cimerli), biosimilar, 0.1 mg | 114 | $225 | $518 |
| New patient office visit (45-59 min) | 100 | $117 | $280 |
| Compounded drug, not otherwise classified | 70 | $74 | $182 |
| Principal care management services for a single high-risk disease, each additional 30 minutes of clinical staff time directed by health care professional, per calendar month | 46 | $37 | $100 |
| Injection, bevacizumab, 10 mg | 36 | $37 | $150 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 33 | $110 | $285 |
| 2d ultrasound scan of eye tissue and structures | 24 | $38 | $305 |
| Removal of membrane of retina with removal of internal limiting membrane of retina | 21 | $845 | $5,700 |
| Photocoagulation treatment to prevent detachment of retina | 21 | $182 | $1,500 |
| Steroid injection (triamcinolone) | 20 | $1 | $21 |
| New patient office visit, complex (60-74 min) | 19 | $137 | $350 |
| Removal of eye fluid (vitreous) between lens and retina | 14 | $686 | $4,000 |
| Complex repair of detached retina and drainage of eye fluid between lens and retina | 13 | $937 | $6,500 |
| Office visit, established patient, complex (40-54 min) | 12 | $143 | $240 |
Industry Payment Transparency
Open Payments through 2024 ↗Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
Payments by company (2024)
Associated products mentioned in payments ›
Most payments (61%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. McClellan is a mixed practice specialist, with above-average Medicare volume (top 1% in TX), and low-engagement industry engagement.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. McClellan experienced with eye injection (vabysmo/faricimab)?
Does Dr. McClellan receive payments from pharmaceutical companies?
How do Dr. McClellan's costs compare to other ophthalmologys in Dallas?
What does Data Coverage mean?
Is this data up to date?
Explore related providers
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology